Last edition
News about Clinical Trials
Corsair Pharma Collaborates with InstantGMP to Enhance Quality for Clinical Trials
Corsair Pharma is revolutionizing pulmonary arterial hypertension (PAH) treatment with its first product candidate: a prodrug of treprostinil delivered via a proprietary transdermal patch.
Clinical Trials | 30/01/2025 | By Aishwarya | 363
Tris Pharma Reveals Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial of Cebranopadol
This dual-NMR agonist has the potential to deliver significant pain relief comparable to opioids with minimized risk of significant side effects, dependence and addiction by leveraging the body’s pain biology modulation processes, synergizing the analgesic and safety characteristics of the NOP receptor with the analgesic advantages of the MOP receptor.
Clinical Trials | 23/01/2025 | By Aishwarya | 638
Advarra Launches Comprehensive Solution to Improve Collaboration on Clinical Trials
The new offering combines the Longboat technology acquired by Advarra in 2020, which now has over 225,000 users, with Advarra's study startup delivery program and industry-adopted single sign-on capabilities.
Clinical Trials | 22/01/2025 | By Aishwarya | 956
TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion
The company successfully completed an FDA-recommended study of isomyosamine that demonstrated clinical safety throughout 13 weeks of treatment at all dose levels evaluated.
Clinical Trials | 16/01/2025 | By Aishwarya | 580
CARsgen Initiates Investigator-Initiated Trial for Allogeneic CD19/CD20 CAR-T Therapy
KJ-C2219 is developed based on CARsgen's THANK-u Plus platform and is designed for the treatment of hematologic malignancies and autoimmune diseases.
Clinical Trials | 02/01/2025 | By Aishwarya | 519
CStone Submits Clinical Trial Application in Australia for CS2009
CS2009 features an innovative molecular design that targets PD-1, VEGFA, and CTLA-4 simultaneously, maintaining balanced affinity for PD-1 and CTLA-4.
Clinical Trials | 23/12/2024 | By Aishwarya | 278
Pharming Unveils Positive Topline Data in Pediatric Clinical Trial of Leniolisib
Pharming plans to include data from this 4-11-year-old trial in regulatory filings worldwide for the approval of leniolisib for pediatric patients with APDS, beginning in 2025.
Clinical Trials | 13/12/2024 | By Aishwarya | 361
The enrollment of the first patient in Taiwan extends the recent expansion of the HARMONIC™ trial into Asia, where there is a notably higher prevalence of never-smoker NSCLC patients compared to Western populations.
Clinical Trials | 10/12/2024 | By Aishwarya | 314
Epigenic Therapeutics to Initiate Clinical Development of EPI-003
This first-in-human study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EPI-003 in Nucleos(t)ide Analogue-Treated, Chronic Hepatitis B Patients.
Clinical Trials | 20/11/2024 | By Aishwarya | 720
GlycoNex Signs Manufacturing Deal with Sterling for GNX102-ADC Clinical Trial Production
GNX102-ADC combines GlycoNex's proprietary monoclonal antibody (mAb), GNX102, and cytotoxic drug therapies to elicit cellular cytotoxicity to target cancer cells with high specificity.
Clinical Trials | 13/11/2024 | By Aishwarya | 341
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy